[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases].

doi:10.1157/13088772

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases].

Medicina clinica - 13 May 2006

Alonso-Navarro Hortensia, Jiménez-Jiménez Félix J, García-Agúndez José A

Abstract excerpt

There are a great number of polymorphic genes in the human genome. Many of them codify enzymes that metabolizes drugs and xenobiotic agents, including carcinogens. Among the better known of them, there are a number of isozymes of the microsomal oxidative system (CYP3A4, CYP2C9, CYP2C19 y CYP2D6). This article reviews the following issues: a) frequency of presentation of the "poor metabolizer" genotype and/or...

Topics

Aryl Hydrocarbon Hydroxylases
Cytochrome P-450 CYP2C19
Drug-Related Side Effects and Adverse Reactions
Genetic Predisposition to Disease
Humans
Mixed Function Oxygenases
Pharmacogenetics
Polymorphism, Genetic

Source

Open in PubMed

Identifiers

PMID: 16759580
DOI: 10.1157/13088772

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics